Safety of TeaCrine®, a non-habituating, naturally-occurring purine alkaloid over eight weeks of continuous use

Table 3 Cardiovascular safety markers, part II

Variable	T1	T2	T3	Time*group	Timegroupgender
RR Interval (ms)
PLA	1011 ± 148	991 ± 147	976 ± 113	Time p = 0.23	GTGe p = 0.68
LD	1095 ± 240	1041 ± 185	1035 ± 212	G*T p = 0.55
HD	987 ± 213	1043 ± 221	1007 ± 198	G*T p = 0.55
PR Interval (ms)
PLA	155 ± 25	155 ± 18	156 ± 20	Time p = 0.49	GTGe p = 0.42
LD	153 ± 18	153 ± 20	154 ± 17	G*T p = 0.33
HD	150 ± 24	144 ± 24	143 ± 19	G*T p = 0.33
QRS Duration (ms)
PLA	95 ± 11	91 ± 22	96 ± 12	Time p = 0.32	GTGe p = 0.25
LD	93 ± 12	93 ± 11	94 ± 11	G*T p = 0.41
HD	92 ± 13	92 ± 12	92 ± 12	G*T p = 0.41
QT Interval (ms)
PLA	428 ± 27	424 ± 31	424 ± 25	Time p = 0.33	GTGe p = 0.38
LD	427 ± 40	424 ± 36	419 ± 38	G*T p = 0.36
HD	409 ± 26	614 ± 904	418 ± 38	G*T p = 0.36
QTc Interval (ms)
PLA	429 ± 17	426 ± 19	427 ± 22	Time p = 0.89	GTGe p = 0.35
LD	421 ± 24	422 ± 22	419 ± 23	G*T p = 0.33
HD	414 ± 19	417 ± 20	419 ± 27	G*T p = 0.33
QT Dispersion (ms)
PLA	38 ± 25	33 ± 18	36 ± 42	Time p = 0.78	GTGe p = 0.11
LD	35 ± 21	51 ± 90	38 ± 25	G*T p = 0.51
HD	41 ± 27	32 ± 21	32 ± 27	G*T p = 0.51
P Axis (degrees)
PLA	54 ± 31	65 ± 12	59 ± 25	Time p = 0.66	GTGe p = 0.88
LD	52 ± 37	53 ± 37	53 ± 35	*GT p = 0.033**
HD	61 ± 15	54 ± 19	59 ± 17	*GT p = 0.033**
R Axis (degrees)
PLA	73 ± 32	78 ± 26	76 ± 33	Time p = 0.81	GTGe p = 0.13
LD	74 ± 25	67 ± 33	72 ± 26	G*T p = 0.38
HD	85 ± 9	84 ± 9	84 ± 11	G*T p = 0.38
T Axis (degrees)
PLA	54 ± 20	415 ± 1587	59 ± 14	Time p = 0.15	GTGe p = 0.34
LD	61 ± 17	438 ± 1653	60 ± 17	G*T p = 0.90
HD	200 ± 634	312 ± 1160	60 ± 17	G*T p = 0.90

Abbreviations: PLA Placebo, LD Theacrine Low Dose, HD Theacrine High Dose, G Group, T Time, Ge Gender
Items in bold indicate a significant effect (p < 0.05) was observed